Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript

And you also see, like AbbVie making Humira unbranded. That could play well with patients and clinicians, it’s really hard to say. What I love about Rani is that we’re not going to be playing. Even though we may use a biosimilar as our drug substance in our final drug product, we’re not a biosimilars company. We’re making novel products out of — making biobetters, if you will, or novel products out of a biosimilar, so dosing schedules are different. We’re shooting for, with RT-111 as an example, getting better near term efficacy, faster PASI scores, and then potentially even elevating in the maintenance phase as Arvinder referenced the efficacy, we think there’s some potential there. So we’re really looking for those opportunities, not just doing a one for one replacement where it’s just a pill, though that is profound, we think, in and of itself.

So I think as it relates to Rani, that’s kind of how we look at this. Whether there’s more, whether there’s fewer, it doesn’t really impact our strategy.

John Vandermosten: Okay, great. Thanks a lot. I appreciate it.

Talat Imran: Thanks, John.

Operator: And thank you. [Operator Instructions] And I am showing no further questions. I would now like to turn the call back over to Talat for closing remarks.

Talat Imran: Thank you, Justin. This concludes our fourth quarter and full year 2023 financial results and corporate update conference call. Thank you again, everyone, for joining us this afternoon.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.